Analysts expect the company to post earnings of $4.76, representing a 10.4% drop from the corresponding period of the ...

Amgen Inc. (NASDAQ:AMGN) is one of the stocks on Jim Cramer’s recent game plan. Cramer said that he heard good things about the company during the JPMorgan Healthcare Conference, as he commented: With ...

Amgen Inc. reports fourth-quarter earnings today after the bell, putting the spotlight on how the $185.6 billion biotechnology giant plans to navigate a year marked by significant biosimilar ...

Amgen Inc. (NASDAQ:AMGN) is included among the 15 Best S&P 500 Dividend Stocks to Buy in 2026. On January 20, Bernstein ...

In its upcoming report, Amgen (AMGN) is predicted by Wall Street analysts to post quarterly earnings of $4.74 per share, reflecting a decline of 10.7% compared to the same period last year. Revenues ...

Amgen (AMGN) stock is downgraded at Bernstein as the brokerage says 2026 may be a “waiting year” for the company. Read more here.

High cholesterol is one of the most common and manageable risk factors for heart disease. Millions of adults are prescribed cholesterol-lowering drugs to reduce low-density lipoprotein (LDL) ...

An updated edition of the December 16, 2025, article. An aging U.S. population is becoming a first-order driver of consumption reallocation. Going by the data from the United States Census Bureau, by ...

Dow Jones biotech giant Amgen, along with fellow biotech stocks Gilead and Vertex, are due to report fourth-quarter earnings ...

For this list, we screened for S&P 500 companies with a market cap of at least $10 billion and identified stable dividend ...

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2026, according to Statista. The oncology segment alone is expected to generate $232 billion in sales this year.

The Trump-Vance administration took office on Jan. 20, 2025. The White House proceeded to dismantle the U.S. Agency for International Development, which funded LGBTQ and intersex rights organizations ...